Regeneron Pharmaceuticals' Cash from Operations fell 729.33% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 billion, marking a year-over-year increase of 1263.21%. This contributed to the annual value of $5.0 billion for FY2025, which is 1263.21% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Cash from Operations stood at $1.2 billion for Q4 2025, which was down 729.33% from $1.6 billion recorded in Q3 2025.
Regeneron Pharmaceuticals' 5-year Cash from Operations high stood at $3.4 billion for Q3 2021, and its period low was $354.0 million during Q2 2024.
In the last 5 years, Regeneron Pharmaceuticals' Cash from Operations had a median value of $1.2 billion in 2025 and averaged $1.3 billion.
In the last 5 years, Regeneron Pharmaceuticals' Cash from Operations soared by 144235.16% in 2021 and then crashed by 8157.66% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Cash from Operations stood at $2.4 billion in 2021, then decreased by 27.51% to $1.7 billion in 2022, then plummeted by 36.64% to $1.1 billion in 2023, then increased by 15.89% to $1.3 billion in 2024, then decreased by 7.29% to $1.2 billion in 2025.
Its last three reported values are $1.2 billion in Q4 2025, $1.6 billion for Q3 2025, and $1.1 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value